Incyte Corporation (BIT:1INCY)
Italy · Delayed Price · Currency is EUR | Market Cap | 17.17B +55.4% |
| Revenue (ttm) | 4.65B +21.5% |
| Net Income | 1.24B +6,631.4% |
| EPS | 6.12 +7,175.4% |
| Shares Out | n/a |
| PE Ratio | 13.83 |
| Forward PE | 12.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 88.94 |
| Previous Close | 88.94 |
| Day's Range | 88.94 - 88.94 |
| 52-Week Range | 57.66 - 96.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced Phase 2 results from Cohort 1 of the Progress study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 inhibitor,...
Incyte announces clinical data from two Phase 2 studies of INCA033989
Incyte (INCY) announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody...
Incyte announces results from Phase 3 frontMIND trial of tafasitamab
Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and l...
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF &...
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survi...
Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy to diversify revenue streams, accelerate pipeline assets, and drive growth through business development and targeted launches. Key programs in hematology and immunology are advancing, with several pivotal trials and major data readouts expected by 2027.
Incyte price target raised to $107 from $90 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Incyte (INCY) to $107 from $90 and keeps a Perform rating on the shares after the company announced the acquisition…
Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal
After Incyte (INCY) announced it has entered into an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B, Jefferies analyst Maury Raycroft said the deal…
Incyte Transcript: M&A announcement
Acquisition of a phase III-ready asset in von Willebrand disease strengthens the hematology portfolio, with $1.25B upfront and $750M in milestones. VGA039 offers a differentiated, once-monthly therapy with blockbuster potential and strong regulatory alignment.
Incyte Press release: M&A announcement
Incyte issued a press release on June 8, 2026, disclosing material business information to investors.
Incyte Slides: M&A announcement
Incyte has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disor...
Incyte to acquire Vega Therapeutics for $1.25B
Incyte (INCY) announced it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to recei...
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders.
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the m...
Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossif...
Incyte announces results from Phase 3 frontMIND trial on tafasitamab
Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and l...
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death...
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.
Incyte Proxy statement: Proxy filing
Incyte filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference.
Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound
Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target The firm is concerned that there is no clear pathway for revenue growth to return…
Incyte initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target